143 related articles for article (PubMed ID: 16598965)
1. Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration.
Mannaert E; Vermeulen A; Remmerie B; Bouhours P; Levron JC
Encephale; 2005; 31(5 Pt 1):609-15. PubMed ID: 16598965
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia.
Eerdekens M; Van Hove I; Remmerie B; Mannaert E
Schizophr Res; 2004 Sep; 70(1):91-100. PubMed ID: 15246468
[TBL] [Abstract][Full Text] [Related]
3. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients.
Thyssen A; Rusch S; Herben V; Quiroz J; Mannaert E
J Clin Pharmacol; 2010 Sep; 50(9):1011-21. PubMed ID: 20097933
[TBL] [Abstract][Full Text] [Related]
4. Long-acting risperidone: a review of its use in schizophrenia.
Harrison TS; Goa KL
CNS Drugs; 2004; 18(2):113-32. PubMed ID: 14728058
[TBL] [Abstract][Full Text] [Related]
5. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial.
Green AI; Brunette MF; Dawson R; Buckley P; Wallace AE; Hafez H; Herz M; Narasimhan M; Noordsy DL; O'Keefe C; Sommi RW; Steinbook RM; Weeks M
J Clin Psychiatry; 2015 Oct; 76(10):1359-65. PubMed ID: 26302441
[TBL] [Abstract][Full Text] [Related]
6. The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study.
Walling DP; Hassman HA; Anta L; Ochoa L; Ayani I; Martínez J; Gutierro I
Drug Des Devel Ther; 2021; 15():4371-4382. PubMed ID: 34703212
[TBL] [Abstract][Full Text] [Related]
7. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.
Gefvert O; Eriksson B; Persson P; Helldin L; Björner A; Mannaert E; Remmerie B; Eerdekens M; Nyberg S
Int J Neuropsychopharmacol; 2005 Mar; 8(1):27-36. PubMed ID: 15710053
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
10. Clinical review of a long-acting, injectable formulation of risperidone.
Knox ED; Stimmel GL
Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service.
Castberg I; Spigset O
Ther Drug Monit; 2005 Feb; 27(1):103-6. PubMed ID: 15665755
[TBL] [Abstract][Full Text] [Related]
12. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of risperidone in different application forms - Comparing long-acting injectable and oral formulations.
Schoretsanitis G; de Leon J; Haen E; Stegmann B; Hiemke C; Gründer G; Paulzen M
Eur Neuropsychopharmacol; 2018 Jan; 28(1):130-137. PubMed ID: 29153926
[TBL] [Abstract][Full Text] [Related]
14. Risperidone plasma levels, clinical response and side-effects.
Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
Edwards NC; Rupnow MF; Pashos CL; Botteman MF; Diamond RJ
Pharmacoeconomics; 2005; 23(3):299-314. PubMed ID: 15836010
[TBL] [Abstract][Full Text] [Related]
16. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone.
Schoretsanitis G; Spina E; Hiemke C; de Leon J
Expert Rev Clin Pharmacol; 2017 Sep; 10(9):965-981. PubMed ID: 28699847
[TBL] [Abstract][Full Text] [Related]
18. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study.
Bai YM; Ting Chen T; Chen JY; Chang WH; Wu B; Hung CH; Kuo Lin W
J Clin Psychiatry; 2007 Aug; 68(8):1218-25. PubMed ID: 17854246
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone.
Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
J Clin Pharmacol; 2015 Jan; 55(1):93-103. PubMed ID: 25043337
[TBL] [Abstract][Full Text] [Related]
20. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
